Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages 327-333

  Maddocks, Kami ^a   Wei, Lai ^a   Rozewski, Darlene ^a   Jiang, Yao ^a   Zhao, Yuan ^a   Adusumilli, Mikhil ^a   Pierceall, William E ^a   Doykin, Camille ^a   Cardone, Michael H ^a   Jones, Jeffrey A ^a   Flynn, Joseph ^a   Andritsos, Leslie A ^a   Grever, Michael R ^a   Byrd, John C ^a   Johnson, Amy J ^a   Phelps, Mitch A ^a   Blum, Kristie A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CREATININE; FLAVOPIRIDOL; LENALIDOMIDE; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CATHETER INFECTION; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERIDINES; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 84925348918     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23946     Document Type: Article

References (42)

1. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006;24:437-443.
2. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006;7:480-488.
3. Byrd J, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
4. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006;24:5343-5349.
5. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
6. Wendtner CM, Hillmen P, Mahadevan D. Final results of a multicenter phase 1 study of lenalidomide in patients with relapased or refractory chronic lymphocytic leukemia. Leuk Lymph 2012;53:417-423.
7. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
8. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406-11411.
9. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464.
10. Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study. Ann Oncol 2013;24:2892-2897.
11. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 2006;108:618-621.
12. Mangiameli DP, Blansfield JA, Kachaia S, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 2007;5:38.
13. Reddy N, Hernandez-Illizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45.
14. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-386.
15. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-1273.
16. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525.
17. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117:2127-2135.
18. Kitada S, Zapata J, Andreef M, Reed J. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-397.
19. Yu C, Rahmani M, Dai Y, et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003;63:1822-1833.
20. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-{kappa}B activation induced by various carcinogens and inflammatory agents through inhibition of I{kappa}B{alpha} kinase and p65 phosphorylation: Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004;279:4750-4759.
21. Bible KC, Bible RHJ, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-2428.
22. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-5437.
23. Garriga J, Javaraman AL, Limon A, et al. A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130. Cell Cycle 2004;3:1320-1330.
24. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-465.
25. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-472.
26. Lin TS, Howard OM, Neuberg DS, et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymph 2002;43:793-797.
27. Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253-1257.
28. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hourbolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805. Clin Cancer Res 2005;11:4176-4181.
29. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113:2637-2645.
30. Blum KA, Ruppert AS, Woyach JA, et al. Risk factors for tumor lysis syndrome in patients wtih chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011;1444-1451.
31. Ji J, Mould DR, Blum KA, et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphoctyic leukemia patients treated with flavopiridol. Clin Cancer Res 2013;19:1269-1280.
32. Lin TL, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically High-risk disease. J Clin Oncol 2009;27:6012-6018.
33. Hussain SR, Lucas DM, Johsnon AJ, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilizaiton of intracellular calcium. Blood 2008;111:3190-3199.
34. Pierceall WE, Lornblau SM, Carlson NE, et al. Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients. Abstract A907, AACR Annual Meeting 2012.
35. Pierceall WE, Lornblau SM, Carlson NE, et al. BH3 profiling discriminates response to cytarabbine-based treatement of acute myelogenous leukemia. Mol Can Ther 2013;12:2940-2949.
36. Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targes and determinates of response in myeloid malignancies. Leukemia 2014;28:1657-1665.
37. Vo TT, Ryan J, Carrasco R, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012;151:344-355.
38. Ni Chonghaile T, Sarosiek KA, Bo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334:1129-1133.
39. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosiis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemai updating the national cancer Institute-working group 1996 guidelines. Blood 2008;111:5445-5456.
40. Liu Q, Farley KL, Johnson AJ. Development and validation of a highly sensitive liquid chrmoatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Drug Monit 2008;30:620-627.
41. Ni W, Ji J, Dai Z, et al. Flavopiridol pharmacogenetics: Clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PloS One 2010;5:e13792
42. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects of hemodialysis. J Clin Pharmacol 2007;479120:1466-1475.